Harrow (HROW) Long-Term Deferred Tax (2019 - 2020)
Harrow (HROW) recorded quarterly Long-Term Deferred Tax of $15.8 million in Q4 2020, up 4.16% quarter-over-quarter from $15.2 million in Q4 2019, and up 4.16% on a YoY basis from $15.2 million in Q1 2020.
Harrow (HROW) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
Harrow's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $15.8 million for Q4 2020.
- In Q4 2020, Long-Term Deferred Tax rose 4.16% year-over-year to $15.8 million; the TTM figure through Dec 2020 stood at $15.8 million (up 4.16% YoY), while the FY2020 annual figure was $15.8 million, up 4.16% from the prior year.
- Long-Term Deferred Tax was $15.8 million for Q4 2020 at Harrow, up from $15.2 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $15.8 million in Q4 2020 to a low of $15.2 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 15.84 Mn |
| Dec 31, 2019 | 15.20 Mn |